{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:33:20Z","timestamp":1753738400581,"version":"3.40.3"},"publisher-location":"Cham","reference-count":115,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030964047"},{"type":"electronic","value":"9783030964054"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/5584_2021_655","type":"book-chapter","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T15:04:40Z","timestamp":1642172680000},"page":"79-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elasticity-Associated Functionality and Inhibition of the HIV Protease"],"prefix":"10.1007","author":[{"given":"Dean","family":"Sherry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Worth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasien","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"655_CR1","doi-asserted-by":"publisher","unstructured":"Baxter JD, Chasanov WM, Adams J (2016) An update on HIV-1 protease inhibitor resistance. J AIDS Clin Res 7. https:\/\/doi.org\/10.4172\/2155-6113.1000581","DOI":"10.4172\/2155-6113.1000581"},{"key":"655_CR2","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1126\/science.1187816","volume":"328","author":"JD Bloom","year":"2010","unstructured":"Bloom JD, Gong LI, Baltimore D (2010) Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328:1272\u20131275. https:\/\/doi.org\/10.1126\/science.1187816","journal-title":"Science"},{"key":"655_CR3","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1128\/AAC.42.11.2775","volume":"42","author":"D Boden","year":"1998","unstructured":"Boden D, Markowitz M (1998) Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 42:2775\u20132783","journal-title":"Antimicrob Agents Chemother"},{"issue":"Pt 3","key":"655_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1099\/0022-1317-77-3-419","volume":"77","author":"AM Borman","year":"1996","unstructured":"Borman AM, Paulous S, Clavel F (1996) Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J Gen Virol 77(Pt 3):419\u2013426. https:\/\/doi.org\/10.1099\/0022-1317-77-3-419","journal-title":"J Gen Virol"},{"key":"655_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nsmb785","volume":"11","author":"JAG Briggs","year":"2004","unstructured":"Briggs JAG, Simon MN, Gross I, Kr\u00e4usslich H-G, Fuller SD, Vogt VM, Johnson MC (2004) The stoichiometry of Gag protein in HIV-1. Nat Struct Mol Biol 11:672\u2013675. https:\/\/doi.org\/10.1038\/nsmb785","journal-title":"Nat Struct Mol Biol"},{"key":"655_CR03","doi-asserted-by":"crossref","unstructured":"Brik A, Wong C-H (2003) HIV-1 protease: mechanism and drug discovery. Org Biomol Chem 1:5\u201314","DOI":"10.1039\/b208248a"},{"key":"655_CR6","doi-asserted-by":"publisher","first-page":"18149","DOI":"10.1039\/C9CP02504A","volume":"21","author":"O Caldararu","year":"2019","unstructured":"Caldararu O, Kumar R, Oksanen E, Logan DT, Ryde U (2019) Are crystallographic B-factors suitable for calculating protein conformational entropy? Phys Chem Chem Phys 21:18149\u201318160. https:\/\/doi.org\/10.1039\/C9CP02504A","journal-title":"Phys Chem Chem Phys"},{"key":"655_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jmb.2011.03.038","volume":"410","author":"MW Chang","year":"2011","unstructured":"Chang MW, Torbett BE (2011) Accessory mutations maintain stability in drug-resistant HIV-1 protease. J Mol Biol 410:756\u2013760. https:\/\/doi.org\/10.1016\/j.jmb.2011.03.038","journal-title":"J Mol Biol"},{"key":"655_CR8","doi-asserted-by":"publisher","first-page":"21433","DOI":"10.1074\/jbc.270.37.21433","volume":"270","author":"Z Chen","year":"1995","unstructured":"Chen Z, Li Y, Schock HB, Hall D, Chen E, Kuo LC (1995) Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. J Biol Chem 270:21433\u201321436. https:\/\/doi.org\/10.1074\/jbc.270.37.21433","journal-title":"J Biol Chem"},{"key":"655_CR9","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3390\/v2071411","volume":"2","author":"F Clavel","year":"2010","unstructured":"Clavel F, Mammano F (2010) Role of gag in HIV resistance to protease inhibitors. Viruses 2:1411\u20131426. https:\/\/doi.org\/10.3390\/v2071411","journal-title":"Viruses"},{"key":"655_CR10","doi-asserted-by":"publisher","first-page":"12141","DOI":"10.1021\/bi049459m","volume":"43","author":"JC Clemente","year":"2004","unstructured":"Clemente JC, Moose RE, Hemrajani R, Whitford LRS, Govindasamy L, Reutzel R, McKenna R, Agbandje-McKenna M, Goodenow MM, Dunn BM (2004) Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. Biochemistry 43:12141\u201312151. https:\/\/doi.org\/10.1021\/bi049459m","journal-title":"Biochemistry"},{"key":"655_CR11","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1038\/s41598-017-03260-4","volume":"7","author":"FM Codo\u00f1er","year":"2017","unstructured":"Codo\u00f1er FM, Pe\u00f1a R, Blanch-Lombarte O, Jimenez-Moyano E, Pino M, Vollbrecht T, Clotet B, Martinez-Picado J, Draenert R, Prado JG (2017) Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to protease inhibitors. Sci Rep 7:3717. https:\/\/doi.org\/10.1038\/s41598-017-03260-4","journal-title":"Sci Rep"},{"key":"655_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/bip.20993","volume":"89","author":"KL Damm","year":"2008","unstructured":"Damm KL, Ung PMU, Quintero JJ, Gestwicki JE, Carlson HA (2008) A poke in the eye: inhibiting HIV-1 protease through its flap-recognition pocket. Biopolymers 89:643\u2013652. https:\/\/doi.org\/10.1002\/bip.20993","journal-title":"Biopolymers"},{"key":"655_CR13","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1128\/jvi.70.6.3763-3769.1996","volume":"70","author":"L Doyon","year":"1996","unstructured":"Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, Lamarre D (1996) Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70:3763\u20133769","journal-title":"J Virol"},{"key":"655_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.str.2007.01.006","volume":"15","author":"JE Foulkes-Murzycki","year":"2007","unstructured":"Foulkes-Murzycki JE, Scott WRP, Schiffer CA (2007) Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure 15:225\u2013233. https:\/\/doi.org\/10.1016\/j.str.2007.01.006","journal-title":"Structure"},{"key":"655_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1110\/ps.33202","volume":"11","author":"DI Freedberg","year":"2002","unstructured":"Freedberg DI, Ishima R, Jacob J, Wang Y-X, Kustanovich I, Louis JM, Torchia DA (2002) Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations. Protein Sci 11:221\u2013232","journal-title":"Protein Sci"},{"key":"655_CR16","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","volume":"59","author":"AK Ghosh","year":"2016","unstructured":"Ghosh AK, Osswald HL, Prato G (2016) Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS. J Med Chem 59:5172\u20135208. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01697","journal-title":"J Med Chem"},{"key":"655_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1021\/bi501088e","volume":"54","author":"NE Goldfarb","year":"2015","unstructured":"Goldfarb NE, Ohanessian M, Biswas S, McGee TD, Mahon BP, Ostrov DA, Garcia J, Tang Y, McKenna R, Roitberg A, Dunn BM (2015) Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr\/Leu89Met: mechanisms for the loss of Saquinavir binding potency. Biochemistry 54:422\u2013433. https:\/\/doi.org\/10.1021\/bi501088e","journal-title":"Biochemistry"},{"key":"655_CR18","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1073\/pnas.86.15.5781","volume":"86","author":"HG G\u00f6ttlinger","year":"1989","unstructured":"G\u00f6ttlinger HG, Sodroski JG, Haseltine WA (1989) Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 86:5781\u20135785","journal-title":"Proc Natl Acad Sci U S A"},{"key":"655_CR19","doi-asserted-by":"publisher","first-page":"9282","DOI":"10.1021\/bi00029a002","volume":"34","author":"SV Gulnik","year":"1995","unstructured":"Gulnik SV, Suvorov LI, Liu B, Yu B, Anderson B, Mitsuya H, Erickson JW (1995) Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282\u20139287","journal-title":"Biochemistry"},{"key":"655_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0083-6729(00)58026-1","volume":"58","author":"S Gulnik","year":"2000","unstructured":"Gulnik S, Erickson JW, Xie D (2000) HIV protease: enzyme function and drug resistance. Vitam Horm 58:213\u2013256","journal-title":"Vitam Horm"},{"key":"655_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0014-5793(90)81171-J","volume":"269","author":"A Gustchina","year":"1990","unstructured":"Gustchina A, Weber IT (1990) Comparison of inhibitor binding in HIV-1 protease and in non-viral aspartic proteases: the role of the flap. FEBS Lett 269:269\u2013272. https:\/\/doi.org\/10.1016\/0014-5793(90)81171-J","journal-title":"FEBS Lett"},{"key":"655_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/prot.340100406","volume":"10","author":"A Gustchina","year":"1991","unstructured":"Gustchina A, Weber IT (1991) Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 10:325\u2013339. https:\/\/doi.org\/10.1002\/prot.340100406","journal-title":"Proteins"},{"key":"655_CR23","doi-asserted-by":"publisher","unstructured":"Haynes BF, Burton DR, Mascola JR (2019) Multiple roles for HIV broadly neutralizing antibodies. Sci Transl Med 11. https:\/\/doi.org\/10.1126\/scitranslmed.aaz2686","DOI":"10.1126\/scitranslmed.aaz2686"},{"key":"655_CR24","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/00002030-200006160-00018","volume":"14","author":"K Hertogs","year":"2000","unstructured":"Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, Miller V, Larder BA (2000) Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14:1203\u20131210. https:\/\/doi.org\/10.1097\/00002030-200006160-00018","journal-title":"AIDS"},{"key":"655_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1073\/pnas.0508452103","volume":"103","author":"V Hornak","year":"2006","unstructured":"Hornak V, Okur A, Rizzo RC, Simmerling C (2006) HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. PNAS 103:915\u2013920. https:\/\/doi.org\/10.1073\/pnas.0508452103","journal-title":"PNAS"},{"key":"655_CR26","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1021\/jm0609162","volume":"50","author":"T Hou","year":"2007","unstructured":"Hou T, Yu R (2007) Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with Amprenavir and two Amprenavir-related inhibitors: mechanism for binding and drug resistance. J Med Chem 50:1177\u20131188. https:\/\/doi.org\/10.1021\/jm0609162","journal-title":"J Med Chem"},{"key":"655_CR27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1080\/21645515.2016.1276138","volume":"13","author":"DC Hsu","year":"2017","unstructured":"Hsu DC, O\u2019Connell RJ (2017) Progress in HIV vaccine development. Hum Vaccin Immunother 13:1018\u20131030. https:\/\/doi.org\/10.1080\/21645515.2016.1276138","journal-title":"Hum Vaccin Immunother"},{"key":"655_CR28","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0969-2126(99)80172-5","volume":"7","author":"R Ishima","year":"1999","unstructured":"Ishima R, Freedberg DI, Wang YX, Louis JM, Torchia DA (1999) Flap opening and dimer-interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Structure 7:1047\u20131055","journal-title":"Structure"},{"key":"655_CR29","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1006\/jmbi.2000.4321","volume":"305","author":"R Ishima","year":"2001","unstructured":"Ishima R, Louis JM, Torchia DA (2001) Characterization of two hydrophobic methyl clusters in HIV-1 protease by NMR spin relaxation in solution. J Mol Biol 305:515\u2013521. https:\/\/doi.org\/10.1006\/jmbi.2000.4321","journal-title":"J Mol Biol"},{"key":"655_CR30","first-page":"215","volume":"11","author":"VA Johnson","year":"2003","unstructured":"Johnson VA, Brun-V\u00e9zinet F, Clotet B, Conway B, D\u2019Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD, International AIDS Society-USA Drug Resistance Mutations Group (2003) Drug resistance mutations in HIV-1. Top HIV Med 11:215\u2013221","journal-title":"Top HIV Med"},{"key":"655_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1021\/ja993084o","volume":"122","author":"K Kahn","year":"2000","unstructured":"Kahn K, Bruice TC (2000) Transition-state and ground-state structures and their interaction with the active-site residues in catechol O-methyltransferase. J Am Chem Soc 122:46\u201351. https:\/\/doi.org\/10.1021\/ja993084o","journal-title":"J Am Chem Soc"},{"key":"655_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1089\/apc.2007.0099","volume":"22","author":"R Kim","year":"2008","unstructured":"Kim R, Baxter JD (2008) Protease inhibitor resistance update: where are we now? AIDS Patient Care STDs 22:267\u2013277. https:\/\/doi.org\/10.1089\/apc.2007.0099","journal-title":"AIDS Patient Care STDs"},{"key":"655_CR33","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1021\/ja00108a056","volume":"117","author":"EE Kim","year":"1995","unstructured":"Kim EE, Baker CT, Dwyer MD, Murcko MA, Rao BG, Tung RD, Navia MA (1995) Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 117:1181\u20131182. https:\/\/doi.org\/10.1021\/ja00108a056","journal-title":"J Am Chem Soc"},{"key":"655_CR34","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.chembiol.2004.08.010","volume":"11","author":"NM King","year":"2004","unstructured":"King NM, Prabu-Jeyabalan M, Nalivaika EA, Schiffer CA (2004) Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol 11:1333\u20131338. https:\/\/doi.org\/10.1016\/j.chembiol.2004.08.010","journal-title":"Chem Biol"},{"key":"655_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/108729104323038874","volume":"18","author":"M Kozal","year":"2004","unstructured":"Kozal M (2004) Review: cross-resistance patterns among HIV protease inhibitors. AIDS Patient Care STDs 18:199\u2013208. https:\/\/doi.org\/10.1089\/108729104323038874","journal-title":"AIDS Patient Care STDs"},{"key":"655_CR36","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1073\/pnas.88.7.2773","volume":"88","author":"J Kuriyan","year":"1991","unstructured":"Kuriyan J, Weis WI (1991) Rigid protein motion as a model for crystallographic temperature factors. Proc Natl Acad Sci U S A 88:2773\u20132777. https:\/\/doi.org\/10.1073\/pnas.88.7.2773","journal-title":"Proc Natl Acad Sci U S A"},{"key":"655_CR37","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.immuni.2018.04.029","volume":"48","author":"PD Kwong","year":"2018","unstructured":"Kwong PD, Mascola JR (2018) HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 48:855\u2013871. https:\/\/doi.org\/10.1016\/j.immuni.2018.04.029","journal-title":"Immunity"},{"key":"655_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12977-018-0443-0","volume":"15","author":"E Landais","year":"2018","unstructured":"Landais E, Moore PL (2018) Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers. Retrovirology 15:61. https:\/\/doi.org\/10.1186\/s12977-018-0443-0","journal-title":"Retrovirology"},{"key":"655_CR39","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-0-12-381270-4.00019-6","volume":"487","author":"A Leaver-Fay","year":"2011","unstructured":"Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R, Kaufman K, Renfrew PD, Smith CA, Sheffler W, Davis IW, Cooper S, Treuille A, Mandell DJ, Richter F, Ban Y-EA, Fleishman SJ, Corn JE, Kim DE, Lyskov S, Berrondo M, Mentzer S, Popovi\u0107 Z, Havranek JJ, Karanicolas J, Das R, Meiler J, Kortemme T, Gray JJ, Kuhlman B, Baker D, Bradley P (2011) Rosetta3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 487:545\u2013574. https:\/\/doi.org\/10.1016\/B978-0-12-381270-4.00019-6","journal-title":"Methods Enzymol"},{"key":"655_CR40","first-page":"131","volume":"10","author":"E Lefebvre","year":"2008","unstructured":"Lefebvre E, Schiffer CA (2008) Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev 10:131\u2013142","journal-title":"AIDS Rev"},{"key":"655_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12981-017-0174-7","volume":"14","author":"H Li","year":"2017","unstructured":"Li H, Omange RW, Plummer FA, Luo M (2017) A novel HIV vaccine targeting the protease cleavage sites. AIDS Res Ther 14:51. https:\/\/doi.org\/10.1186\/s12981-017-0174-7","journal-title":"AIDS Res Ther"},{"key":"655_CR42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1054-3589(07)55008-8","volume":"55","author":"JM Louis","year":"2007","unstructured":"Louis JM, Ishima R, Torchia DA, Weber IT (2007) HIV-1 protease: structure, dynamics, and inhibition. Adv Pharmacol 55:261\u2013298. https:\/\/doi.org\/10.1016\/S1054-3589(07)55008-8","journal-title":"Adv Pharmacol"},{"key":"655_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/minf.201800053","volume":"37","author":"A Luchi","year":"2018","unstructured":"Luchi A, Angelina E, Bogado L, Forli S, Olson A, Peruchena N (2018) Flap-site fragment restores back wild-type behaviour in resistant form of HIV protease. Mol Inform 37:e1800053. https:\/\/doi.org\/10.1002\/minf.201800053","journal-title":"Mol Inform"},{"key":"655_CR44","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1021\/bi9802521","volume":"37","author":"I Luque","year":"1998","unstructured":"Luque I, Todd MJ, G\u00f3mez J, Semo N, Freire E (1998) Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis. Biochemistry 37:5791\u20135797. https:\/\/doi.org\/10.1021\/bi9802521","journal-title":"Biochemistry"},{"key":"655_CR45","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/med.1012","volume":"21","author":"PP Mager","year":"2001","unstructured":"Mager PP (2001) The active site of HIV-1 protease. Med Res Rev 21:348\u2013353","journal-title":"Med Res Rev"},{"key":"655_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/prot.1057","volume":"43","author":"B Mahalingam","year":"2001","unstructured":"Mahalingam B, Louis JM, Hung J, Harrison RW, Weber IT (2001) Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease\/substrate analogue complexes. Proteins 43:455\u2013464. https:\/\/doi.org\/10.1002\/prot.1057","journal-title":"Proteins"},{"key":"655_CR47","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1128\/jvi.69.2.701-706.1995","volume":"69","author":"M Markowitz","year":"1995","unstructured":"Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, Ho DD (1995) Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 69:701\u2013706","journal-title":"J Virol"},{"key":"655_CR48","doi-asserted-by":"publisher","first-page":"33231","DOI":"10.1074\/jbc.271.52.33231","volume":"271","author":"B Maschera","year":"1996","unstructured":"Maschera B, Darby G, Pal\u00fa G, Wright LL, Tisdale M, Myers R, Blair ED, Furfine ES (1996) Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J Biol Chem 271:33231\u201333235. https:\/\/doi.org\/10.1074\/jbc.271.52.33231","journal-title":"J Biol Chem"},{"key":"655_CR49","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00894-006-0121-3","volume":"13","author":"H Meiselbach","year":"2007","unstructured":"Meiselbach H, Horn AHC, Harrer T, Sticht H (2007) Insights into amprenavir resistance in E35D HIV-1 protease mutation from molecular dynamics and binding free-energy calculations. J Mol Model 13:297\u2013304. https:\/\/doi.org\/10.1007\/s00894-006-0121-3","journal-title":"J Mol Model"},{"key":"655_CR50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.antiviral.2009.07.006","volume":"85","author":"L Men\u00e9ndez-Arias","year":"2010","unstructured":"Men\u00e9ndez-Arias L (2010) Molecular basis of human immunodeficiency virus drug resistance: an update. Antivir Res 85:210\u2013231. https:\/\/doi.org\/10.1016\/j.antiviral.2009.07.006","journal-title":"Antivir Res"},{"key":"655_CR51","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1021\/ja2095766","volume":"134","author":"S Mittal","year":"2012","unstructured":"Mittal S, Cai Y, Nalam MN, Bolon DNA, Schiffer CA (2012) Hydrophobic core flexibility modulates enzyme activity in HIV-1 protease. J Am Chem Soc 134:4163\u20134168. https:\/\/doi.org\/10.1021\/ja2095766","journal-title":"J Am Chem Soc"},{"key":"655_CR52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/0006-291x(89)90008-9","volume":"159","author":"ML Moore","year":"1989","unstructured":"Moore ML, Bryan WM, Fakhoury SA, Magaard VW, Huffman WF, Dayton BD, Meek TD, Hyland L, Dreyer GB, Metcalf BW (1989) Peptide substrates and inhibitors of the HIV-1 protease. Biochem Biophys Res Commun 159:420\u2013425. https:\/\/doi.org\/10.1016\/0006-291x(89)90008-9","journal-title":"Biochem Biophys Res Commun"},{"key":"655_CR53","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1021\/bi027019u","volume":"42","author":"S Muzammil","year":"2003","unstructured":"Muzammil S, Ross P, Freire E (2003) A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42:631\u2013638. https:\/\/doi.org\/10.1021\/bi027019u","journal-title":"Biochemistry"},{"key":"655_CR54","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1515\/hsz-2014-0162","volume":"395","author":"P Naicker","year":"2014","unstructured":"Naicker P, Sayed Y (2014) Non-B HIV-1 subtypes in sub-Saharan Africa: impact of subtype on protease inhibitor efficacy. Biol Chem 395:1151\u20131161. https:\/\/doi.org\/10.1515\/hsz-2014-0162","journal-title":"Biol Chem"},{"key":"655_CR55","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1080\/07391102.2012.736774","volume":"31","author":"P Naicker","year":"2013","unstructured":"Naicker P, Achilonu I, Fanucchi S, Fernandes M, Ibrahim MAA, Dirr HW, Soliman MES, Sayed Y (2013) Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance. J Biomol Struct Dyn 31:1370\u20131380. https:\/\/doi.org\/10.1080\/07391102.2012.736774","journal-title":"J Biomol Struct Dyn"},{"key":"655_CR56","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1111\/febs.13084","volume":"281","author":"P Naicker","year":"2014","unstructured":"Naicker P, Stoychev S, Dirr HW, Sayed Y (2014) Amide hydrogen exchange in HIV-1 subtype B and C proteases \u2013 insights into reduced drug susceptibility and dimer stability. FEBS J 281:5395\u20135410. https:\/\/doi.org\/10.1111\/febs.13084","journal-title":"FEBS J"},{"key":"655_CR57","doi-asserted-by":"publisher","first-page":"5368","DOI":"10.1128\/JVI.02531-09","volume":"84","author":"MNL Nalam","year":"2010","unstructured":"Nalam MNL, Ali A, Altman MD, Reddy GSKK, Chellappan S, Kairys V, Ozen A, Cao H, Gilson MK, Tidor B, Rana TM, Schiffer CA (2010) Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance. J Virol 84:5368\u20135378. https:\/\/doi.org\/10.1128\/JVI.02531-09","journal-title":"J Virol"},{"key":"655_CR58","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/337615a0","volume":"337","author":"MA Navia","year":"1989","unstructured":"Navia MA, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, Herber WK, Sigal IS, Darke PL, Springer JP (1989) Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337:615\u2013620. https:\/\/doi.org\/10.1038\/337615a0","journal-title":"Nature"},{"key":"655_CR59","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nsb0495-274","volume":"2","author":"LK Nicholson","year":"1995","unstructured":"Nicholson LK, Yamazaki T, Torchia DA, Grzesiek S, Bax A, Stahl SJ, Kaufman JD, Wingfield PT, Lam PY, Jadhav PK (1995) Flexibility and function in HIV-1 protease. Nat Struct Biol 2:274\u2013280. https:\/\/doi.org\/10.1038\/nsb0495-274","journal-title":"Nat Struct Biol"},{"key":"655_CR60","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.chom.2017.07.010","volume":"22","author":"Y Nishimura","year":"2017","unstructured":"Nishimura Y, Martin MA (2017) Of mice, macaques, and men: broadly neutralizing antibody immunotherapy for HIV-1. Cell Host Microbe 22:207\u2013216. https:\/\/doi.org\/10.1016\/j.chom.2017.07.010","journal-title":"Cell Host Microbe"},{"key":"655_CR61","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1093\/nar\/gkq1314","volume":"39","author":"M Ohishi","year":"2011","unstructured":"Ohishi M, Nakano T, Sakuragi S, Shioda T, Sano K, Sakuragi J (2011) The relationship between HIV-1 genome RNA dimerization, virion maturation and infectivity \u2020. Nucleic Acids Res 39:3404\u20133417. https:\/\/doi.org\/10.1093\/nar\/gkq1314","journal-title":"Nucleic Acids Res"},{"key":"655_CR62","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pbiomolbio.2004.07.005","volume":"88","author":"H Ohtaka","year":"2005","unstructured":"Ohtaka H, Freire E (2005) Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol 88:193\u2013208. https:\/\/doi.org\/10.1016\/j.pbiomolbio.2004.07.005","journal-title":"Prog Biophys Mol Biol"},{"key":"655_CR63","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1110\/ps.0206402","volume":"11","author":"H Ohtaka","year":"2002","unstructured":"Ohtaka H, Vel\u00e1zquez-Campoy A, Xie D, Freire E (2002) Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci 11:1908\u20131916. https:\/\/doi.org\/10.1110\/ps.0206402","journal-title":"Protein Sci"},{"key":"655_CR64","doi-asserted-by":"publisher","first-page":"23699","DOI":"10.1074\/jbc.274.34.23699","volume":"274","author":"DB Olsen","year":"1999","unstructured":"Olsen DB, Stahlhut MW, Rutkowski CA, Schock HB, vanOlden AL, Kuo LC (1999) Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors. J Biol Chem 274:23699\u201323701. https:\/\/doi.org\/10.1074\/jbc.274.34.23699","journal-title":"J Biol Chem"},{"key":"655_CR65","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jmb.2011.03.053","volume":"410","author":"A \u00d6zen","year":"2011","unstructured":"\u00d6zen A, Halilo\u011flu T, Schiffer CA (2011) Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope. J Mol Biol 410:726\u2013744. https:\/\/doi.org\/10.1016\/j.jmb.2011.03.053","journal-title":"J Mol Biol"},{"key":"655_CR66","doi-asserted-by":"publisher","first-page":"15993","DOI":"10.1073\/pnas.1414063111","volume":"111","author":"A \u00d6zen","year":"2014","unstructured":"\u00d6zen A, Lin K-H, Kurt Yilmaz N, Schiffer CA (2014) Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease. Proc Natl Acad Sci U S A 111:15993\u201315998. https:\/\/doi.org\/10.1073\/pnas.1414063111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"655_CR02","doi-asserted-by":"crossref","unstructured":"Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB (1995) In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 69:5228\u20135235","DOI":"10.1128\/jvi.69.9.5228-5235.1995"},{"key":"655_CR67","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/00002030-200203080-00014","volume":"16","author":"CF Perno","year":"2002","unstructured":"Perno CF, Cozzi-Lepri A, Balotta C, Bertoli A, Violin M, Monno L, Zauli T, Montroni M, Ippolito G, d\u2019Arminio-Monforte A (2002) Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS 16:619\u2013624. https:\/\/doi.org\/10.1097\/00002030-200203080-00014","journal-title":"AIDS"},{"key":"655_CR68","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1110\/ps.03468904","volume":"13","author":"AL Perryman","year":"2004","unstructured":"Perryman AL, Lin J-H, McCammon JA (2004) HIV-1 protease molecular dynamics of a wild-type and of the V82F\/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci 13:1108\u20131123. https:\/\/doi.org\/10.1110\/ps.03468904","journal-title":"Protein Sci"},{"key":"655_CR69","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/j.1747-0285.2009.00943.x","volume":"75","author":"AL Perryman","year":"2010","unstructured":"Perryman AL, Zhang Q, Soutter HH, Rosenfeld R, McRee DE, Olson AJ, Elder JE, Stout CD (2010) Fragment-based screen against HIV protease. Chem Biol Drug Des 75:257\u2013268. https:\/\/doi.org\/10.1111\/j.1747-0285.2009.00943.x","journal-title":"Chem Biol Drug Des"},{"key":"655_CR70","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0022-2836(02)00301-7","volume":"319","author":"S Piana","year":"2002","unstructured":"Piana S, Carloni P, Parrinello M (2002a) Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. J Mol Biol 319:567\u2013583. https:\/\/doi.org\/10.1016\/S0022-2836(02)00301-7","journal-title":"J Mol Biol"},{"key":"655_CR71","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1110\/ps.0206702","volume":"11","author":"S Piana","year":"2002","unstructured":"Piana S, Carloni P, Rothlisberger U (2002b) Drug resistance in HIV-1 protease: flexibility-assisted mechanism of compensatory mutations. Protein Sci 11:2393\u20132402. https:\/\/doi.org\/10.1110\/ps.0206702","journal-title":"Protein Sci"},{"key":"655_CR72","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1021\/ct300082q","volume":"8","author":"AA Polyansky","year":"2012","unstructured":"Polyansky AA, Kuzmanic A, Hlevnjak M, Zagrovic B (2012) On the contribution of linear correlations to quasi-harmonic conformational entropy in proteins. J Chem Theory Comput 8:3820\u20133829. https:\/\/doi.org\/10.1021\/ct300082q","journal-title":"J Chem Theory Comput"},{"key":"655_CR73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0969-2126(02)00720-7","volume":"10","author":"M Prabu-Jeyabalan","year":"2002","unstructured":"Prabu-Jeyabalan M, Nalivaika E, Schiffer CA (2002) Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10:369\u2013381","journal-title":"Structure"},{"key":"655_CR74","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1128\/JVI.77.2.1306-1315.2003","volume":"77","author":"M Prabu-Jeyabalan","year":"2003","unstructured":"Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA (2003) Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol 77:1306\u20131315. https:\/\/doi.org\/10.1128\/JVI.77.2.1306-1315.2003","journal-title":"J Virol"},{"key":"655_CR75","doi-asserted-by":"publisher","first-page":"12446","DOI":"10.1128\/JVI.78.22.12446-12454.2004","volume":"78","author":"M Prabu-Jeyabalan","year":"2004","unstructured":"Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA (2004) Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol 78:12446\u201312454. https:\/\/doi.org\/10.1128\/JVI.78.22.12446-12454.2004","journal-title":"J Virol"},{"key":"655_CR76","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1021\/ja9913838","volume":"122","author":"JL Radkiewicz","year":"2000","unstructured":"Radkiewicz JL, Brooks CL (2000) Protein dynamics in enzymatic catalysis: exploration of dihydrofolate reductase. J Am Chem Soc 122:225\u2013231. https:\/\/doi.org\/10.1021\/ja9913838","journal-title":"J Am Chem Soc"},{"key":"655_CR77","doi-asserted-by":"publisher","first-page":"11956","DOI":"10.1021\/ja504096m","volume":"136","author":"DA Ragland","year":"2014","unstructured":"Ragland DA, Nalivaika EA, Nalam MNL, Prachanronarong KL, Cao H, Bandaranayake RM, Cai Y, Kurt-Yilmaz N, Schiffer CA (2014) Drug resistance conferred by mutations outside the active site through alterations in the dynamic and structural ensemble of HIV-1 protease. J Am Chem Soc 136:11956\u201311963. https:\/\/doi.org\/10.1021\/ja504096m","journal-title":"J Am Chem Soc"},{"key":"655_CR78","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1128\/AAC.00574-10","volume":"54","author":"S-Y Rhee","year":"2010","unstructured":"Rhee S-Y, Taylor J, Fessel WJ, Kaufman D, Towner W, Troia P, Ruane P, Hellinger J, Shirvani V, Zolopa A, Shafer RW (2010) HIV-1 protease mutations and protease inhibitor cross-resistance. Antimicrob Agents Chemother 54:4253\u20134261. https:\/\/doi.org\/10.1128\/AAC.00574-10","journal-title":"Antimicrob Agents Chemother"},{"key":"655_CR79","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/(SICI)1097-0134(19980701)32:1<7::AID-PROT3>3.0.CO;2-K","volume":"32","author":"SW Rick","year":"1998","unstructured":"Rick SW, Erickson JW, Burt SK (1998) Reaction path and free energy calculations of the transition between alternate conformations of HIV-1 protease. Proteins 32:7\u201316","journal-title":"Proteins"},{"key":"655_CR80","doi-asserted-by":"publisher","first-page":"13835","DOI":"10.1021\/bi980612k","volume":"37","author":"TW Ridky","year":"1998","unstructured":"Ridky TW, Kikonyogo A, Leis J, Gulnik S, Copeland T, Erickson J, Wlodawer A, Kurinov I, Harrison RW, Weber IT (1998) Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate. Biochemistry 37:13835\u201313845. https:\/\/doi.org\/10.1021\/bi980612k","journal-title":"Biochemistry"},{"key":"655_CR81","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","author":"NA Roberts","year":"1990","unstructured":"Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Kr\u00f6hn A (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248:358\u2013361","journal-title":"Science"},{"key":"655_CR82","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1021\/bi9716074","volume":"37","author":"RB Rose","year":"1998","unstructured":"Rose RB, Craik CS, Stroud RM (1998) Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 37:2607\u20132621. https:\/\/doi.org\/10.1021\/bi9716074","journal-title":"Biochemistry"},{"key":"655_CR83","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/(SICI)1097-0134(19981101)33:2<295::AID-PROT12>3.0.CO;2-F","volume":"33","author":"L Schaffer","year":"1998","unstructured":"Schaffer L, Verkhivker GM (1998) Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization. Proteins 33:295\u2013310","journal-title":"Proteins"},{"key":"655_CR84","doi-asserted-by":"publisher","first-page":"31957","DOI":"10.1074\/jbc.271.50.31957","volume":"271","author":"HB Schock","year":"1996","unstructured":"Schock HB, Garsky VM, Kuo LC (1996) Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J Biol Chem 271:31957\u201331963. https:\/\/doi.org\/10.1074\/jbc.271.50.31957","journal-title":"J Biol Chem"},{"key":"655_CR85","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S0969-2126(00)00537-2","volume":"8","author":"WR Scott","year":"2000","unstructured":"Scott WR, Schiffer CA (2000) Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure 8:1259\u20131265","journal-title":"Structure"},{"key":"655_CR86","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/088922299311727","volume":"15","author":"RW Shafer","year":"1999","unstructured":"Shafer RW, Chuang TK, Hsu P, White CB, Katzenstein DA (1999) Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res Hum Retrovir 15:65\u201369. https:\/\/doi.org\/10.1089\/088922299311727","journal-title":"AIDS Res Hum Retrovir"},{"key":"655_CR87","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1111\/j.1742-4658.2010.07771.x","volume":"277","author":"C-H Shen","year":"2010","unstructured":"Shen C-H, Wang Y-F, Kovalevsky AY, Harrison RW, Weber IT (2010) Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. FEBS J 277:3699\u20133714. https:\/\/doi.org\/10.1111\/j.1742-4658.2010.07771.x","journal-title":"FEBS J"},{"key":"655_CR04","doi-asserted-by":"publisher","unstructured":"Sherry D, Worth R, Ismail ZS, Sayed Y (2021) Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: implications for flap dynamics. J Mol Graph Model 106:107931. https:\/\/doi.org\/10.1016\/j.jmgm.2021.107931","DOI":"10.1016\/j.jmgm.2021.107931"},{"key":"655_CR88","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","volume":"19","author":"D Sok","year":"2018","unstructured":"Sok D, Burton DR (2018) Recent progress in broadly neutralizing antibodies to HIV. Nat Immunol 19:1179\u20131188. https:\/\/doi.org\/10.1038\/s41590-018-0235-7","journal-title":"Nat Immunol"},{"key":"655_CR89","doi-asserted-by":"publisher","first-page":"10928","DOI":"10.1021\/bi980784h","volume":"37","author":"MA Swairjo","year":"1998","unstructured":"Swairjo MA, Towler EM, Debouck C, Abdel-Meguid SS (1998) Structural role of the 30\u2019s loop in determining the ligand specificity of the human immunodeficiency virus protease. Biochemistry 37:10928\u201310936. https:\/\/doi.org\/10.1021\/bi980784h","journal-title":"Biochemistry"},{"key":"655_CR90","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.2010.1004","volume":"304","author":"MA Thompson","year":"2010","unstructured":"Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, Gatell JM, G\u00fcnthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT, International AIDS Society-USA (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304:321\u2013333. https:\/\/doi.org\/10.1001\/jama.2010.1004","journal-title":"JAMA"},{"key":"655_CR91","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jmb.2004.02.052","volume":"338","author":"Y Tie","year":"2004","unstructured":"Tie Y, Boross PI, Wang Y-F, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT (2004) High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 338:341\u2013352. https:\/\/doi.org\/10.1016\/j.jmb.2004.02.052","journal-title":"J Mol Biol"},{"key":"655_CR92","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1111\/j.1742-4658.2005.04923.x","volume":"272","author":"Y Tie","year":"2005","unstructured":"Tie Y, Boross PI, Wang Y-F, Gaddis L, Liu F, Chen X, Tozser J, Harrison RW, Weber IT (2005) Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J 272:5265\u20135277. https:\/\/doi.org\/10.1111\/j.1742-4658.2005.04923.x","journal-title":"FEBS J"},{"key":"655_CR93","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1021\/cb300611p","volume":"8","author":"T Tiefenbrunn","year":"2013","unstructured":"Tiefenbrunn T, Forli S, Baksh MM, Chang MW, Happer M, Lin Y-C, Perryman AL, Rhee J-K, Torbett BE, Olson AJ, Elder JH, Finn MG, Stout CD (2013) Small molecule regulation of protein conformation by binding in the Flap of HIV protease. ACS Chem Biol 8:1223\u20131231. https:\/\/doi.org\/10.1021\/cb300611p","journal-title":"ACS Chem Biol"},{"key":"655_CR94","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/cbdd.12227","volume":"83","author":"T Tiefenbrunn","year":"2014","unstructured":"Tiefenbrunn T, Forli S, Happer M, Gonzalez A, Tsai Y, Soltis M, Elder JH, Olson AJ, Stout CD (2014) Crystallographic fragment based drug discovery: use of a brominated fragment library targeting HIV protease. Chem Biol Drug Des 83:141\u2013148. https:\/\/doi.org\/10.1111\/cbdd.12227","journal-title":"Chem Biol Drug Des"},{"key":"655_CR95","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1006\/jmbi.1998.2090","volume":"283","author":"MJ Todd","year":"1998","unstructured":"Todd MJ, Semo N, Freire E (1998) The structural stability of the HIV-1 protease. J Mol Biol 283:475\u2013488. https:\/\/doi.org\/10.1006\/jmbi.1998.2090","journal-title":"J Mol Biol"},{"key":"655_CR96","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1021\/bi001013s","volume":"39","author":"MJ Todd","year":"2000","unstructured":"Todd MJ, Luque I, Vel\u00e1zquez-Campoy A, Freire E (2000) Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F\/I84V active site resistant mutant. Biochemistry 39:11876\u201311883. https:\/\/doi.org\/10.1021\/bi001013s","journal-title":"Biochemistry"},{"key":"655_CR97","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1749-6632.2001.tb03909.x","volume":"946","author":"J T\u00f6zs\u00e9r","year":"2001","unstructured":"T\u00f6zs\u00e9r J (2001) HIV inhibitors: problems and reality. Ann N Y Acad Sci 946:145\u2013159","journal-title":"Ann N Y Acad Sci"},{"key":"655_CR01","unstructured":"UNAIDS (2021) Global HIV & AIDS statistics \u2014 Fact sheet [WWW Document]. https:\/\/www.unaids.org\/en\/resources\/fact-sheet"},{"key":"655_CR98","doi-asserted-by":"publisher","first-page":"6468","DOI":"10.1021\/jm5008352","volume":"57","author":"PM-U Ung","year":"2014","unstructured":"Ung PM-U, Dunbar JB, Gestwicki JE, Carlson HA (2014) An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases. J Med Chem 57:6468\u20136478. https:\/\/doi.org\/10.1021\/jm5008352","journal-title":"J Med Chem"},{"key":"655_CR99","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1073\/pnas.111152698","volume":"98","author":"A Vel\u00e1zquez-Campoy","year":"2001","unstructured":"Vel\u00e1zquez-Campoy A, Todd MJ, Vega S, Freire E (2001) Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci 98:6062\u20136067. https:\/\/doi.org\/10.1073\/pnas.111152698","journal-title":"Proc Natl Acad Sci"},{"key":"655_CR100","first-page":"165","volume":"5","author":"A Vel\u00e1zquez-Campoy","year":"2003","unstructured":"Vel\u00e1zquez-Campoy A, Vega S, Fleming E, Bacha U, Sayed Y, Dirr HW, Freire E (2003) Protease inhibition in African subtypes of HIV-1. AIDS Rev 5:165\u2013171","journal-title":"AIDS Rev"},{"key":"655_CR101","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(10)60676-9","volume":"376","author":"PA Volberding","year":"2010","unstructured":"Volberding PA, Deeks SG (2010) Antiretroviral therapy and management of HIV infection. Lancet 376:49\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(10)60676-9","journal-title":"Lancet"},{"key":"655_CR102","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0022-2836(02)00400-X","volume":"320","author":"X Wang","year":"2002","unstructured":"Wang X, Minasov G, Shoichet BK (2002) Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol 320:85\u201395. https:\/\/doi.org\/10.1016\/S0022-2836(02)00400-X","journal-title":"J Mol Biol"},{"key":"655_CR103","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.4155\/fmc.15.44","volume":"7","author":"IT Weber","year":"2015","unstructured":"Weber IT, Kneller DW, Wong-Sam A (2015) Highly resistant HIV-1 proteases and strategies for their inhibition. Future Med Chem 7:1023\u20131038. https:\/\/doi.org\/10.4155\/fmc.15.44","journal-title":"Future Med Chem"},{"key":"655_CR104","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/prot.25826","volume":"88","author":"TR Weikl","year":"2020","unstructured":"Weikl TR, Hemmateenejad B (2020) Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance. Proteins 88:476\u2013484. https:\/\/doi.org\/10.1002\/prot.25826","journal-title":"Proteins"},{"key":"655_CR105","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2009.10.003","volume":"85","author":"AMJ Wensing","year":"2010","unstructured":"Wensing AMJ, van Maarseveen NM, Nijhuis M (2010) Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antivir Res 85:59\u201374. https:\/\/doi.org\/10.1016\/j.antiviral.2009.10.003","journal-title":"Antivir Res"},{"key":"655_CR106","first-page":"132","volume":"24","author":"AM Wensing","year":"2017","unstructured":"Wensing AM, Calvez V, G\u00fcnthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD (2017) 2017 update of the drug resistance mutations in HIV-1. Top Antivir Med 24:132\u2013133","journal-title":"Top Antivir Med"},{"key":"655_CR107","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1042\/BCJ20180692","volume":"476","author":"A Williams","year":"2019","unstructured":"Williams A, Basson A, Achilonu I, Dirr HW, Morris L, Sayed Y (2019) Double trouble? Gag in conjunction with double insert in HIV protease contributes to reduced DRV susceptibility. Biochem J 476:375\u2013384. https:\/\/doi.org\/10.1042\/BCJ20180692","journal-title":"Biochem J"},{"key":"655_CR108","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350000500101","volume":"5","author":"MA Winters","year":"2000","unstructured":"Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC (2000) Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn community programs for clinical research on AIDS. Antivir Ther (Lond) 5:57\u201363","journal-title":"Antivir Ther (Lond)"},{"key":"655_CR109","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1126\/science.2548279","volume":"245","author":"A Wlodawer","year":"1989","unstructured":"Wlodawer A, Miller M, Jask\u00f3lski M, Sathyanarayana BK, Baldwin E, Weber IT, Selk LM, Clawson L, Schneider J, Kent SB (1989) Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245:616\u2013621","journal-title":"Science"},{"key":"655_CR110","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.1128\/jvi.77.8.4836-4847.2003","volume":"77","author":"TD Wu","year":"2003","unstructured":"Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ, Shafer RW (2003) Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 77:4836\u20134847. https:\/\/doi.org\/10.1128\/jvi.77.8.4836-4847.2003","journal-title":"J Virol"},{"key":"655_CR111","doi-asserted-by":"publisher","unstructured":"Zondagh J, Basson AE, Achilonu I, Morris L, Dirr HW, Sayed Y (2019) Drug susceptibility and replication capacity of a rare HIV-1 subtype C protease hinge region variant. Antivir Ther (Lond). https:\/\/doi.org\/10.3851\/IMP3308","DOI":"10.3851\/IMP3308"}],"container-title":["Advances in Experimental Medicine and Biology","Protein Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/5584_2021_655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T23:55:57Z","timestamp":1674431757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/5584_2021_655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030964047","9783030964054"],"references-count":115,"URL":"https:\/\/doi.org\/10.1007\/5584_2021_655","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"type":"print","value":"0065-2598"},{"type":"electronic","value":"2214-8019"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"6 August 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}